The top 5 biosimilar conference articles in 2024 highlight significant progress in the biosimilar landscape, including ...

Elie Bahou, PharmD, highlights how vertical integration in the biosimilar industry streamlines costs, improves supply reliability, accelerates market adoption, and enhances patient access, while ...

The top legal stories in biosimilars from 2024 emphasize the ongoing struggle between ensuring timely patient access and ...

In 2024, significant biosimilar approvals were granted by the American and European regulatory agencies, including the first ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

The top gastroenterology biosimilar news from 2024 highlight fluctuations in the adalimumab biosimilar market throughout the ...

Number 3: Sandoz's biosimilar denosumab (Jubbonti/Wyost) has demonstrated analytical, pharmacokinetic, pharmacodynamic, and ...

A recent study showed similar safety and efficacy of a bevacizumab biosimilar compared with the reference product (Avastin) ...

China's trastuzumab biosimilar market is growing but lags behind European countries, with biosimilars gradually increasing ...

Health Canada has approved Omlyclo, the first omalizumab biosimilar in Canada, for the treatment of chronic idiopathic ...

Elie Bahou, PharmD, senior vice president and system chief pharmacy officer at Providence, discusses strategies to improve equitable access to biologic therapies, including tiered formularies, ...

A systematic review identified 13 strategies, including patient and provider education, empathetic communication, and shared ...